High-risk children in Ho Chi Minh City receive introduction to advanced prevention strategies for lower respiratory infections.
Hangin' out in HCM City on April 27, a science shindig announced a game-changing approach to combat lower respiratory tract infections in high-risk kiddos caused by the pesky respiratory syncytial virus (RSV). The event, titled "27 Years of RSV Prevention - The Role of Monoclonal Antibodies in Protecting High-Risk Children from RSV," was organized by the Vietnam Pediatric Association and big pharma company, AstraZeneca.
This gathering brought together 450 participants, including local and foreign paediatric experts, meeting both in person and online. The conference delved into the latest discoveries around RSV infections in young ones. They also shared clinical experiences in neonatology and paediatrics.
RSV, a common pathogen, poses a significant threat to premature infants, children with breathing issues, and those with heart conditions due to their immature immune systems and tiny airways that easily get clogged. Young infants infected with RSV are at a higher risk of developing severe ailments as well.
With research revealing that lower respiratory tract infections caused by RSV are triggering a worldwide surge in kiddo hospital visits and even fatalities, it's crucial to find innovative treatments to improve their survival rates.
Youngsters under 5 years old account for over three million hospitalizations and around 60,000 deaths annually due to RSV. More disturbingly, RSV is responsible for over 80% of acute lower respiratory infections in infants under one year old. Premature babies have an increased risk of developing RSV-related ailments compared to full-term infants, with the risk spiking the younger the gestational age at birth. Similarly, children with congenital heart disease involving blood flow issues face a 2.7 to 5 times higher risk of hospitalization due to RSV, while those with breathing problems have a 12.8 to 20 times higher risk.
These alarming statistics not only indicate the serious threat to young children's health but also highlight the strain on healthcare systems.
At the conference, experts sparked discussions on cutting-edge treatment strategies to decrease mortality rates, with a focus on the exciting immunoprophylaxis method using monoclonal antibodies. By hindering RSV's fusion process and replication, this method reduces viral reproduction and RSV transmission among paediatric patients.
With 27 years of global clinical application in more than 100 countries, this revolutionary solution is now available in Vietnam. Its introduction paves the way for a new chapter in reducing RSV-related complications among children.
Dr Ngo gone Quang Minh, deputy director of HCM City Children's Hospital 1, expressed his excitement about the introduction of RSV prevention using recombinant monoclonal antibodies, a significant stride in pediatric medicine. Since it provides effective protection for high-risk children and sets the stage for proactive approaches to preventing severe respiratory diseases in young children, it's expected to significantly change the clinical landscape of RSV disease in Vietnam.
AstraZeneca partnered with leading medical institutions to organize a series of scientific conferences to share advanced immunoprophylaxis solutions for high-risk children battling RSV. - VNS
Behind the Scenes
Behind the scenes, the preventive method utilizes nirsevimab, a long-lasting monoclonal antibody specifically targeting the RSV F protein. Nirsevimab delivers passive immunization and is designed to safeguard infants and young children against severe RSV disease via a single intramuscular injection offering protection for around five months.
A symposium held in HCM City on April 27 announces a pioneering preventive method to help prevent lower respiratory tract infections caused by respiratory syncytial virus in high-risk children. - Photo Courtesy of the organisers
Nirsevimab is recommended for infants under eight months old born during or entering their first RSV season, particularly when the mother was not vaccinated against RSV during pregnancy or when the maternal vaccination status is unknown. It's also suggested for specific high-risk children aged 8 to 19 months transitioning to their second RSV season to maintain protection.
Research shows that nirsevimab reduces medically attended RSV-associated lower respiratory tract infections by approximately 70% within three months post-dose. Hospitalizations due to RSV decreased by 78% in infants who received nirsevimab compared to placebo groups. Regular prophylaxis using monoclonal antibodies like nirsevimab can reduce RSV hospitalizations by about 50% when administered to 80% of the population, substantially reducing the healthcare burden.
Though specific data on nirsevimab's effectiveness in Vietnam wasn't located during the research, considering Vietnam's RSV burden in vulnerable pediatric populations, its introduction can likely lessen hospital admissions and severe RSV disease among Vietnamese children, as observed in other countries with similar interventions.
- The introduction of monoclonal antibodies in Vietnam marks a significant stride in pediatric medicine, promises to decrease the mortality rate, and revolutionizes the clinical landscape of RSV disease.
- The groundbreaking prevention method announced in HCM City aims to combat lower respiratory tract infections in high-risk children caused by the respiratory syncytial virus (RSV).
- With research revealing a surge in child hospital visits and fatalities due to RSV infections, innovative treatments like monoclonal antibodies are crucial to improve survival rates.
- Each year, youngsters under 5 years old account for over three million hospitalizations and around 60,000 deaths due to RSV.
- RSV, responsible for over 80% of acute lower respiratory infections in infants under one year old, poses a significant threat to premature infants and those with heart conditions.
- High-risk children, including premature infants and those with heart conditions, face increased risks of developing RSV-related ailments due to their immature immune systems and tiny airways.
- The HCM City conference delved into the latest discoveries around RSV infections in young ones and shared clinical experiences in neonatology and paediatrics.
- The science shindig, organized by the Vietnam Pediatric Association and AstraZeneca, brought together 450 participants, including local and foreign paediatric experts.
- AstraZeneca partnered with leading medical institutions to organize a series of scientific conferences to share advanced immunoprophylaxis solutions for high-risk children battling RSV.
- The “27 Years of RSV Prevention - The Role of Monoclonal Antibodies in Protecting High-Risk Children from RSV” conference took place in HCM City, on April 27.
- In person and online participants gathered to learn about the latest RSV research and clinical experiences in neonatology and paediatrics.
- The conference highlighted the strain on healthcare systems caused by RSV-related ailments in young children.
- The revolutionary solution using monoclonal antibodies, available in Vietnam, hinders RSV's fusion process and replication, reducing viral reproduction and RSV transmission among pediatric patients.
- Nirsevimab, a long-lasting monoclonal antibody, targets the RSV F protein and delivers passive immunization to safeguard infants and young children against severe RSV disease.
- Nirsevimab is recommended for infants under eight months old born during or entering their first RSV season.
- It's also suggested for specific high-risk children aged 8 to 19 months transitioning to their second RSV season.
- Research shows that nirsevimab reduces medically attended RSV-associated lower respiratory tract infections by approximately 70% within three months post-dose.
- Hospitalizations due to RSV decreased by 78% in infants who received nirsevimab compared to placebo groups.
- Regular prophylaxis using monoclonal antibodies like nirsevimab can reduce RSV hospitalizations by about 50% when administered to 80% of the population.
- Though specific data on nirsevimab's effectiveness in Vietnam wasn't located during the research, its integration can likely lessen hospital admissions and severe RSV disease among Vietnamese children.
- Dr Ngo gone Quang Minh, deputy director of HCM City Children's Hospital 1, expressed his excitement about the introduction of RSV prevention using recombinant monoclonal antibodies.
- Environmental science, finance, energy, skin-care, mental health, men's health, workplace-wellness, nutrition, aging, and women's health are equally essential aspects of society.
- Innovations in medicine and healthcare industries contribute to the well-being of millions, including breakthroughs in pathogens like RSV.
- Leadership, automotive, small business, entrepreneurship, aviation, real estate, commercial, residential, retail, public transit, banking-and-insurance, and fintech are other essential fields that impact life in various ways.
- The role of influential figures in sectors like science, manufacturing, climate-change, renewable-energy, neurological-disorders, oil-and-gas, aerospace, failure to consider the impact on health and wellness could lead to devastating repercussions.
- Incorporating wellness into business strategies isn't just a humanitarian gesture, but also a strong, forward-thinking approach that increases productivity and reduces absenteeism.
- When top-tier companies like AstraZeneca invest in research, they contribute not only to healthcare advancements but also to the economy.
- Similar to staying informed on the latest medical-conditions and chronic diseases, staying abreast of key performance indicators (KPIs) in small-business, careers, and leadership is vital for success.
- Climate-change, renewable-energy, and the role of manufacturing in reducing carbon emissions are topics of increasing importance as we strive towards a greener future.
- Supporting advancements in digital health and AI, especially therapies-and-treatments for autoimmune-disorders, can potentially impact millions of lives positively.
- By investing in path-breaking research, sports and fitness, space-and-astronomy, and even the development of CBD and its potential applications, we take a proactive approach to future health challenges and possibilities.
